|1.||Kim, Sung Kyo: 2 articles (05/2008 - 10/2006)|
|2.||Ahn, Dong Kuk: 2 articles (05/2008 - 10/2006)|
|3.||Bae, Yong Chul: 2 articles (05/2008 - 10/2006)|
|4.||Lee, Ho Jeong: 2 articles (05/2008 - 10/2006)|
|5.||Yoon, Young Wook: 2 articles (05/2008 - 10/2006)|
|6.||Ju, Jin Sook: 2 articles (05/2008 - 10/2006)|
|7.||Choi, Hyo Soon: 2 articles (05/2008 - 10/2006)|
|8.||Shin, Seung-Shick: 2 articles (03/2007 - 08/2006)|
|9.||Marín, Yarí E: 2 articles (03/2007 - 08/2006)|
|10.||Namkoong, Jin: 2 articles (03/2007 - 08/2006)|
06/25/2010 - "The results showed that the mGlu5 receptor antagonist MPEP hydrochloride (2-Methyl-6-(phenylethynyl)pyridine hydrochloride) and the mGlu2/3 receptor agonist DCG-IV ((2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine) caused full protection against seizures or increased latency to onset of seizures, whereas the mGlu1 receptor antagonist LY367385 ((S)-(+)-alpha-Amino-4-carboxy-2-methylbenzeneacetic acid) did not produce anticonvulsant efficacy in response to systemically administered soman (1.3 x LD(50)). "
06/01/2008 - "The administration of LY367385 attenuated the increases in the amounts of PSD-associated PKCgamma and Src after transient focal ischemia. "
01/01/1999 - "Furthermore, intraventricular administration of LY367385 reduced hippocampal cell death in gerbils subjected to transient global ischemia. "
02/01/1999 - "(+)-2-Methyl-4-carboxyphenylglycine (LY367385), a potent and selective antagonist of mGlu1a metabotropic glutamate receptors, was neuroprotective in the following in vitro and in vivo models of excitotoxic death: (i) mixed cultures of murine cortical cells transiently exposed to N-methyl-D-aspartate (NMDA); (ii) rats monolaterally infused with NMDA into the caudate nucleus; and (iii) gerbils subjected to transient global ischemia. "
01/01/2002 - "Post-treatment with the group I mGlu receptor antagonists LY367385 and AIDA allowed significant recovery of the paw withdrawal latencies after the onset of the knee joint inflammation. "
05/15/2008 - "Intramuscular pretreatment with 5mM MCPG, non-selective group I/II mGluR antagonist, or MPEP, a selective group I mGluR5 antagonist, produced a significant attenuation of MO-induced hindpaw shaking behaviour and increases in extravasated Evans' blue dye concentration in the masseter muscle while LY367385, a selective group I mGluR1 antagonist, did not affect MO-induced nociceptive behaviour and inflammation in the masseter muscle. "
10/16/2006 - "Intramuscular pretreatment with 5 mM MCPG, non-selective group I/II mGluR antagonist, or MPEP, a selective group I mGluR5 antagonist, produced a significant attenuation of MO-induced hindpaw shaking behaviour and increases in extravasated Evans' blue dye concentration in the masseter muscle while LY367385, a selective group I mGluR1 antagonist, did not affect MO-induced nociceptive behaviour and inflammation in the masseter muscle. "
|4.||Brain Injuries (Brain Injury)
10/01/2003 - "Changes of metabotropic glutamate receptor subtype 1a in diffuse brain injury with secondary brain insults and the effects of 2-methyl-4-carboxyphenylglycine."
11/27/1995 - "The metabotropic glutamate receptor (mGluR) antagonist, alpha-methyl-4-carboxyphenylglycine (MCPG) was administered into the left lateral ventricle 5 min prior to fluid percussion traumatic brain injury (TBI) in the rat. "
06/01/2008 - "We investigated the effects of the metabotropic glutamate receptor 1 (mGluR1) antagonist LY367385 on brain injury after transient (90 min) middle cerebral artery occlusion in the rat and sought to explore their mechanisms. "
09/01/2006 - "LY367385 reduced the immobility time in the forced swim test but induced locomotion in rats subjected to hypoxia. "
09/01/2006 - "Both tested ligands are involved in the motility of rats, however, LY367385 influences hypolocomotion hypoxia-induced."
09/01/2006 - "The obtained results indicated that baclofen and LY367385 given alone or jointly induce an antidepressant-like effect in the forced swim test but only LY367385 possesses such activity in rats that had undergone hypoxia. "
04/15/2005 - "Ventilation (V(E)) and body temperature (T(b)) were measured before and after bilaterally microinjection of kynurenic acid (KYN, 5 nmol/100 nl, an ionotropic glutamatergic receptors antagonist) and alpha-methyl-4-carboxyphenylglycine (MCPG, 10 nmol/100 nl, a metabotropic glutamatergic receptors antagonist) into the RVLM, followed by a 60-min period of hypoxia exposure. "
10/01/2004 - "We measured V E and Tb in 40 adult male Wistar rats (270 to 300 g) before and after intracerebroventricular injection of kynurenic acid (KYN, an ionotropic glutamatergic receptor antagonist), alpha-methyl-4-carboxyphenylglycine (MCPG, a metabotropic glutamatergic receptor antagonist) or vehicle (saline), followed by a 1-h period of hypoxia (7% inspired O2) or normoxia (humidified room air). "
|3.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|4.||metabotropic glutamate receptor type 1
|5.||metabotropic glutamate receptor 5
|6.||Kynurenic Acid (Kynurenate)
|7.||Evans Blue (Blue, Evans)
|10.||Glutamic Acid (Glutamate)